← Leaderboards
Katherine B Peters
Duke University
$1,098,938
Attributed
$2,504,332
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,504,332 · 2
By mechanism
R01$1,584,966 · 1
R44$919,366 · 1
Top collaborators
- Brian J Soher4 shared
- Katherine Havranek1 shared
- Evan Charles Unger1 shared
Most similar at Duke University
Same institution · by research overlap
- John H Sampson$43,413,436
- Darell D Bigner$25,397,506
- Brian J Soher$2,568,106
- Olaf T Von Ramm$3,789,203
- Mark Wesley Dewhirst$12,821,035
Others in their field
Other Rising Stars on “Monitor”
- Jessica Ellis · Technical Resources International, Inc.$46,538,640
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Jeffrey Leintz · National Opinion Research Center$40,628,545
- Joan Grand · Mitre Corporation$32,826,287
- Lauren Miller · Technical Resources International, Inc.$31,120,905
- Walt Lee$25,884,232
Research focus
MonitorBloodProteinsResponseAdultGenesMagnetic Resonance ImagingProgression-Free SurvivalsTumorStandard Of CareEffectivenessBrain NeoplasmsCancer Therapy Evaluation ProgramEarly Phase Clinical TrialBrainAutomationEnzymesDiagnostic BiomarkerAutomobile DrivingClinical Decision-MakingClinical Research SiteClinical TrialsCombinatorialDesign
Grant awards (5)
Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic$919,366
R44 · FY2025 · CA
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma$438,208
R01 · FY2025 · CA
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma$291,737
R01 · FY2024 · CA
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma$462,296
R01 · FY2023 · CA
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma$392,725
R01 · FY2022 · CA